Expert Consensus: American College of Physicians: GLP-1 receptor agonists should be considered for patients with obesity who have not achieved weight loss goals with lifestyle modifications. Endocrine Society: Semaglutide and tirzepatide represent significant advances in obesity pharmacotherapy and should be considered first-line options. Obesity Medicine Association: The dramatic efficacy of GLP-1 and dual agonist medications has fundamentally changed the treatment landscape for obesity. Real-World Effectiveness: Studies of patients using these medications outside clinical trials show: GLP-1s: Similar to clinical trial results (confirming real-world effectiveness) Older medications: Often less effective in real-world than trials (adherence issues) Patient satisfaction: Highest with GLP-1s Bottom Line: Which Works Best
1.7mg 2 ,
Yes, research shows GLP-1 medications like semaglutide and tirzepatide can result in weight loss of 15% to 20% (or more)
King JA, Bernardoni F, Westbrook A, Korb FM, Boehm I, Doose A, Geisler D, Gramatke K, Hellerhoff I, Wolff S, Strobel A, Goschke T, Roessner V, Ehrlich S (2024) Exaggerated frontoparietal control over cognitive effort-based decision-making in young women with anorexia nervosa